Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | PTAFR | P25105 | 4/20 | 0.32 |
| ▸ | FES | P07332 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | MARK3 | P27448 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893897 | 0.81 | FAAH (0.36) | HRH4NAMPT | |
| SCHEMBL7609149 | 0.79 | CYP1A2 (0.53) | NAAA | |
| SCHEMBL7689126 | 0.79 | CYP1A2 (0.53) | NAAA | |
| SCHEMBL7689408 | 0.79 | CYP1A2 (0.53) | NAAA | |
| SCHEMBL6699717 | 0.76 | CHRNB2 (0.41) | PTAFRFESRETMARK3TYK2 | |
| SCHEMBL5265530 | 0.76 | HRH4 (0.32) | HRH4 | |
| SCHEMBL7070178 | 0.74 | CYP3A4 (0.44) | — | |
| SCHEMBL7692290 | 0.73 | KEAP1 (0.38) | HRH4NAAA | |
| SCHEMBL504616 | 0.70 | HRH4 (0.51) | HRH4PTAFRHRH2HRH1 | |
| SCHEMBL810402 | 0.70 | IKBKB (0.46) | HRH4PTAFRHRH2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | DAO, AOC1, SIGMAR1 | HRH4 159/4885PLA2G7 3504/4885PTAFR 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.